Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers

Histopathology

Volumn 44, Issue 1, 2004, Pages 54-63

  Groeger, A M ^a,f   Esposito, V ^b,f   De Luca, A ^b   Cassandro, R ^b   Tonini, G ^c   Ambrogi, V ^d   Baldi, F ^b   Goldfarb, R ^e   Mineo, T C ^d   Baldi, A ^b,g   Wolner, E ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF NORTH TEXAS   (United States)

^f Intl Soc Stud Compar Oncol   (United States)

^g Intl Soc Stud of Compar Oncol ^*  (Italy)

Author keywords

Bax; Bcl 2; Non small cell lung cancer; p53; Prognosis

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LYMPH NODE; MALE; MULTIGENE FAMILY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0842286954     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01750.x     Document Type: Article

References (29)

1. Zochbauer-Muller S, Gazdar AF, Minna JD. Molecular pathogenesis of lung cancer. Annu. Rev. Physiol. 2002: 64; 681-708.
2. Junker K. Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer 2001: 33; S17-S24.
3. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogens 2002: 21; 6898-6907.
4. Passlick B, Izbicki JR, Haussinger K, Tetther O, Pantel K. Immunohistochemical detection of p53 protein is not associated with poor prognosis in non small cell lung cancer. J. Thorac. Cardiovasc. Surg. 1995: 109; 1205-1211.
5. Horio Y, Takahashi T, Kuroishi T et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non small-cell lung cancer. Cancer Res. 1993: 53; 1-4.
6. Dosaka-Akita H, Shindoh M, Fujino M et al. Abnormal p53 expression in primary human lung cancer is associated with histological subtypes and patient smoking history. Am. J. Clin. Pathol. 1994: 102; 660-664.
7. Volm M, Mattern J. Immunohistochemical detection of p53 in non small cell lung cancer. J. Natl Cancer Inst. 1994: 86; 801-802.
8. Esposito V, De Luca A, Baldi A et al. Altered expression of p53 and rb tumor suppressor genes in lung cancer: relationship with survival. Int. J. Oncol. 1996: 9; 439-443.
9. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000: 408; 307-310.
10. Selvakumaran M, Lin HK, Miyashita T et al. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 1994: 9; 1791-1798.
11. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog. Bax, that accelerates programmed cell death. Cell 1993: 74; 609-619.
12. Sedlak TW, Oltvai ZN, Yang E et al. Multiple Bcl-2 family members demonstrate selective dimenzations with Bax. Proc. Natl Acad. Sci. USA 1995: 92; 7834-7838.
13. Boise LH, Gonzalez-Garcia M, Postema CE et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993: 74; 597-608.
14. World Health Organization. Histological typing of lung tumors. 2nd edn. Geneva: World Health Organization, 1981.
15. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Lung, Manual for staging of cancer. 4th edn. Chicago: American Joint Committee on Cancer, 1992: 115-122.
16. McDonnell TJ, Meyn RE, Robertson LE. Implications of apoptotic cell death regulation in cancer therapy. Cancer Biol. 1995: 6; 53-60.
17. Esposito V, Baldi A, De Luca A et al. Prognostic value of p53 in non small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum. Pathol. 1997: 2; 233-237.
18. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res. 2000: 6; 4055-4063.
19. Krajewski S, Blomqvist C, Franssila K et al. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995: 55; 4471-4478.
20. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of bax. a dominant inhibitor of bcl-2. Am. J. Pathol. 1994: 145; 1323-1336.
21. Apolinario RM, van der Valk P, de Jong JS et al. Prognostic value of the expression of p53. bcl-2 and bax oncoproteins, and neovascularization in patients with radically resected non small cell lung cancer. J. Clin. Oncol. 1997: 15; 2456-2466.
22. Han H, Landreneau RJ, Cantucci TS et al. Prognostic value of immunohistochemical expressions of p53. HER-2/neu. and bcl-2 in stage I non-small-cell lung cancer. Hum. Pathol. 2002: 33; 105-110.
23. Hanaoka T, Nakayama J, Haniuda M, Sato TA. Immunohistochemical demonstration of apoptosis-regulated proteins, bcl-2 and bax, in resected non-small-cell lung cancers. Int. J. Clin. Oncol. 2002: 7; 152-158.
24. Pezzella F, Turley H, Kuzu I et al. Bcl-2 protein in non-small cell lung carcinoma. N. Engl. J. Med. 1993: 329; 690-694.
25. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticanc Res. 1995: 15; 503-505.
26. Walker C, Robertson L, Myskow M, Pendleton N, Dixon GR. Expression of bcl-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br. J. Cancer. 1995: 72; 164-169.
27. Ohmura Y, Aoe M, Andou A, Shimizu N. Telomerase activity and bcl-2 expression in non-small cell lung cancer. Clin. Cancer Res. 2000: 6; 2980-2987.
28. Cox G, Walker RA, Muller S, Abrams KR, Steward WP, O'Brien KJ. Does immunointensity account for the differences in prognostic significance of bcl-2 expression in non-small cell lung cancer? Pathol. Oncol. Res. 2000: 6; 87-92.
29. Reeve JG, Xiong J, Morgan J, Bleehen NM. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer. 1996: 73; 1193-1200.